4D Pharma, plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 4D Pharma, plc
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.
Once deemed an intimidating and risky space, microbiome modulator firms are slowly winning over investors as robust clinical data surface, with one company, Microbiotica, recently hitting an EU financing record.
Depending on financing, the company could start a Phase III trial of CBM588 as early as this year, but it’s looking to develop the microbiome therapeutic for a potentially broad array of cancers.
Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Life Sciences Innovation
- GT Biologics
- Longevity Acquisition Corporation